Brought to you by 
Spirogen reacquires rights to SJG136 from Ipsen
17 Jun 2014
Executive Summary
In a new deal that supersedes their original agreement, Ipsen will hand over development of SJG136 to Spirogen. Now called SG2000, the DNA minor groove binder is set to begin National Cancer Institute-sponsored Phase II trials for refractory ovarian tumors and hematological malignancies.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spirogen reacquires rights to SJG136 from Ipsen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice